The Intellectual Property and Science business of Thomson Reuters has unveiled the nominations for the Allicense 2015 Breakthrough Awards, honouring the leading deals of 2014 in Biopharmaceutical Licensing and Mergers and Acquisitions (M&A), as identified by Thomson Reuters Recap, the leading provider of analysis and advice for biopharmaceutical business development.
The awards - to be determined by public vote - will be presented on May 5 at Allicense, a prominent event connecting business development, licensing and M&A professionals throughout pharma, biotech and finance to discuss industry-wide challenges and collaborate on creating a roadmap for the future of pharmaceutical development.
The award nominees—five contenders in each of the two categories—were determined by Thomson Reuters deals analysts after a thorough analysis of Recap information and other criteria that examined numerous deals negotiated throughout 2014.
Members of the biopharmaceutical community are invited to vote for the top breakthrough deals in each category until 6 p.m. PT on May 5.
Allicense will be held on May 5-6 in San Francisco. Interested parties may visit Allicense.com to learn more about this key industry event, how you can register and the details behind the nominations.
